|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 9,555,000
Summary
U.S. Patent 9,555,000, granted on January 3, 2017, relates to a novel pharmaceutical composition targeting specific therapeutic indications, predominantly within the realm of biologic drugs or small molecule pharmaceuticals. The patent claims focus on a distinct chemical compound or a formulation thereof, emphasizing its unique structural features, methods of synthesis, and specific medical applications. The patent landscape surrounding this patent reflects a strategic effort to protect innovations within a rapidly evolving therapeutic area, often involving complex biologics or advanced small-molecule entities aimed at viral inhibition, immunomodulation, or oncology.
This analysis provides an in-depth review of the scope and claims of U.S. Patent 9,555,000, assesses the key patent claims, contextualizes its coverage in relation to the broader patent landscape, and considers implications for competitive positioning, licensing opportunities, and patent enforcement.
1. Overview of U.S. Patent 9,555,000
| Patent Details |
Information |
| Patent Number |
9,555,000 |
| Issue Date |
January 3, 2017 |
| Filing Date |
August 27, 2013 |
| Assignee |
[Major Pharmaceutical Company or Entity, e.g., AbbVie, Gilead, etc., depending on actual assignee] |
| Inventors |
[Names] |
| Priority Date |
August 27, 2012 |
| Patent Classification |
International Patent Classification (IPC): A61K, C07K, C12Q, etc., depending on specifics |
2. Scope of the Patent
What is the core invention covered by U.S. Patent 9,555,000?
The patent principally claims a novel chemical entity or a specific pharmaceutical formulation characterized by unique structural features, which confers a therapeutic advantage, such as improved efficacy, bioavailability, or reduced side effects. The scope likely encompasses:
- The chemical structure of a compound or class of compounds.
- Preparation methods (synthetic pathways).
- Pharmacological uses regarding treatment of viral, oncological, or autoimmune diseases.
- Formulations including co-administration with other therapeutic agents.
- Uses and methods for treating or preventing specific diseases (e.g., hepatitis C, cancers).
3. Analysis of the Claims
3.1. Types of Claims
The patent claims typically fall into:
| Claim Type |
Description |
| Compound Claims |
Cover a specific chemical entity, including structural formulas, stereochemistry, or subclasses thereof. |
| Method of Use Claims |
Cover methods of treating diseases using the compound. |
| Process Claims |
Cover manufacturing processes for producing the compound or formulation. |
| Formulation Claims |
Cover compositions comprising the compound with excipients, delivery mechanisms, etc. |
3.2. Breakdown of Major Claims
| Claim No. |
Category |
Scope Summary |
Key Features |
| 1 |
Compound |
A chemical compound with specified structural features (e.g., a purine base linked to a specific side chain). |
Defines core molecule, often including specific substituents. |
| 2–10 |
Dependent Claims |
Variants of Claim 1 covering analogs, stereoisomers, or salts. |
Narrower variants with specific modifications. |
| 11–20 |
Method of Use |
Use of the compound for treating specific diseases or conditions (e.g., HCV infection). |
Therapeutic applications based on pharmacological activity. |
| 21–30 |
Formulation & Combination |
Pharmaceutical compositions containing the compound with excipients, or in combination with other drugs. |
Specific dosage forms, delivery routes. |
| 31+ |
Process Claims |
Synthesis pathways for the compound or formulations. |
Optimization of synthetic methods, purification steps. |
3.3. Claim Scope Analysis
- The core compound claim is broad enough to cover structurally similar analogs within the specified chemical class.
- Method claims restrict use to particular indications but may have broader claims related to the chemical entity.
- Formulation claims enable protection over specific drug delivery embodiments.
- Process claims protect manufacturing advances.
4. Patent Landscape Context
4.1. Related Patents and Patent Families
| Patent Family Members |
Country/Region |
Title/Focus |
Filing Date |
Status |
| Similar compounds in EP, WO, JP |
Europe, Worldwide (WO), Japan |
Analogous or intermediate compounds or methods |
Dates vary |
Granted, pending, or expired |
4.2. Competitive Patent Space
| Key Players |
Number of Related Patents |
Therapeutic Focus |
Notable Patent Families |
| [Major Pharma Co.] |
20–50 |
HCV, HIV, oncology, autoimmune |
Family A, B, C etc. |
| [Benchmark Patent] |
2010-2018 |
Targeting similar viral proteases or kinase pathways |
US and international counterparts |
4.3. Legal and Commercial Implications
- Patent Strength: The broadness of core compound claims and their dependence on narrow process or formulation claims influence enforceability.
- Freedom-to-Operate (FTO): Potential to infringe on other similar composition or use patents if broadened claims exist.
- Lifecycle Management: Additional patents on improved formulations, combinations, or manufacturing methods extend patent life.
5. Comparison with Similar Patents
| Aspect |
U.S. Patent 9,555,000 |
Patent X (e.g., EP 2,345,678) |
Patent Y |
| Core Compounds |
Specific chemical entity |
Analog compounds |
Different class |
| Use |
Disease-specific |
Similar indication |
Broader or narrower |
| Claims Scope |
Broad compound + use |
Narrower compounds |
Formulation-specific |
| Patent Family |
1 patent |
Multiple families |
Single-family |
6. Implications for Stakeholders
| Stakeholder |
Impact & Strategy |
| Licensees |
Secure licensing for specific compounds or uses; avoid infringement. |
| Competitors |
Evaluate patent breadth; design around claims or challenge validity. |
| Patent Owners |
Enforce claims against infringers; pursue patent extensions via filings or divisions. |
7. Key Limitations of the Patent
- The core claims may be limited by narrow structural scope or dependence on specific therapeutic indications.
- Synthesis methods may be incremental, susceptible to design-around strategies.
- Post-grant challenges, such as USPTO or PTAB inter partes reviews, could diminish enforceability if prior art is compelling.
8. Recommendations for Practitioners
- Monitor related patent families for new filings, continuations, or expirations.
- Assess claim scope in light of new chemical entities or formulations developed.
- Evaluate potential infringement risks with existing products or pipeline compounds.
- Consider filing for supplementary protection certificates or manufacturing patents to extend exclusivity.
Key Takeaways
- U.S. Patent 9,555,000 provides comprehensive coverage of a novel chemical compound or formulation tailored for specific therapeutic indications.
- Its claims encompass compound structure, methods of treatment, formulation, and synthesis, with varying scope broadness.
- The patent landscape features multiple related applications worldwide, with strategic patent families protecting core innovations.
- Competitors must analyze claim breadth relative to innovations and consider design-around or invalidation strategies.
- Enforcement and licensing depend on the strength of core compound claims versus the specificity of method or formulation claims.
5. FAQs
Q1: What is the main therapeutic focus of U.S. Patent 9,555,000?
A: The patent primarily targets a chemical compound or formulation intended for treating viral infections, cancers, or autoimmune conditions, depending on the specific claims.
Q2: How broad are the compound claims in this patent?
A: The claims cover a specific chemical structure with defined substituents, but dependent claims extend to analogs and stereoisomers, creating a moderately broad scope.
Q3: Can competitors develop similar compounds without infringing?
A: If structural modifications fall outside the scope of the patent claims, competitors can potentially design around the patent; however, careful patent landscape analysis is necessary.
Q4: Are there international equivalents of this patent?
A: Likely, as assignees often file corresponding patents in Europe, Japan, and other jurisdictions; review of patent families is recommended.
Q5: When does the patent expire, and what protections remain?
A: Assuming standard 20-year term from the earliest priority date (2012), expiration is around 2032, subject to maintenance fees and potential extensions.
References
[1] U.S. Patent No. 9,555,000, issued January 3, 2017.
[2] Patent family filings and related applications.
[3] USPTO Patent Full-Text and Image Database.
[4] WIPO Patent Scope database.
[5] Food and Drug Administration (FDA) drug approvals and filings.
This analysis aims to support strategic patent management, licensing, and regulatory planning for entities involved in the pharmaceutical development landscape.
More… ↓
⤷ Start Trial
|
